金吾财讯 | 诺和诺德(NVO)盘中股价向好，截止发稿，涨8.51%，报88美元，成交额7.83亿美元。消息面上，公司宣布一项小规模临床试验发现，每周注射一次 20 毫克的减肥药Amycretin可以帮助肥胖和超重患者在 36 周内减轻 22% 的体重。诺和诺德公司开发执行副总裁马丁·朗格 (Martin Lange) 表示：“Amycretin在超重或肥胖人群中的皮下 1b/2a 期结果令我们非常鼓舞。试验结果支持了这种新型单分子 GLP-1 和胰岛淀粉样肽受体激动剂阿米克汀的减肥潜力，我们之前已在口服制剂中看到这种潜力。”根据最新结果，诺和诺德表示目前正计划进一步对Amycretin进行临床开发，用于治疗肥胖和超重成年人。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.